(Q34490092)

2 August 2017

1 reference

title

Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? (English)

1 reference

2 August 2017

1 reference

1 reference

1 reference

1 reference

6

1 reference

2 August 2017

Charlier C

1

1 reference

2 August 2017

Hart E

2

1 reference

2 August 2017

Lefort A

3

1 reference

2 August 2017

Ribaud P

4

1 reference

2 August 2017

Dromer F

5

1 reference

2 August 2017

Lortholary O

7

1 reference

2 August 2017

language of work or name

English

0 references

publication date

31 January 2006

1 reference

Journal of Antimicrobial Chemotherapy

2 August 2017

number of pages

27

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

2 August 2017

volume

57

1 reference

2 August 2017

issue

3

1 reference

2 August 2017

page(s)

384-410

1 reference

The discovery and profile of fluconazole

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Treatment of two cases of cryptococcal meningitis with fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS): successful treatment with fluconazole after failure of amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Administration of fluconazole in children below 1 year of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fluconazole penetration in cerebral parenchyma in humans at steady state

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Biliary concentrations of fluconazole in a patient with candidal cholecystitis: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fluconazole in the management of fungal ocular infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Interaction of Azoles with Rifampin, Phenytoin, and Carbamazepine: In Vitro and Clinical Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Antifungal chemoprophylaxis after blood and marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Alopecia associated with fluconazole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Safety evaluation of chronic fluconazole therapy. Fluconazole Pan-American Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Stevens-Johnson syndrome after fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Can fluconazole concentrations in saliva be used for therapeutic drug monitoring?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Plasma and tissue concentrations of fluconazole and their correlation to breakpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fungal infections in solid-organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fungal infection in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Clinical spectrum of fungal infections after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fluconazole prophylaxis for high-risk liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Prevention of fungal infection in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Epidemiology of fungal infections in solid organ transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Infections in bone marrow transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Towards a targeted, risk-based, antifungal strategy in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Bone Marrow Transplantation Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Prophylactic use of fluconazole in neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Management and outcome of bloodstream infections due to Candida species in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Attributable mortality of nosocomial candidemia, revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Early diagnosis of candidiasis in non-neutropenic critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Candida colonization and subsequent infections in critically ill surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Therapeutic dilemma of fluconazole prophylaxis in intensive care

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Candidemia: the impact of antifungal prophylaxis in a surgical intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fluconazole improves survival in septic shock: a randomized double-blind prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Candidosis in the intensive care unit: a 20-year survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Management of Candida species infections in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Epidemiology of Candida species infections in critically ill non-immunosuppressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Breakthrough fungemia caused by azole-resistant Candida albicans in neutropenic patients with acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Hepatosplenic candidiasis: successful treatment with fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Successful treatment of Candida albicans osteomyelitis with fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Spondylodiskitis due to Candida albicans: report of two patients who were successfully treated with fluconazole and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Candida albicans osteomyelitis in a liver transplant recipient: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fluconazole therapy in Candida albicans spondylodiscitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Successful treatment of candidal osteomyelitis with fluconazole following failure with liposomal amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Successful treatment of Candida albicans osteomyelitis of the spine with fluconazole and surgical debridement: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Candida glabrata spinal osteomyelitis involving two contiguous lumbar vertebrae: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

An unusual cause of vertebral osteomyelitis: Candida species

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Candida prosthetic arthritis: report of a case treated with fluconazole and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Prosthetic joint infections with osteomyelitis due to Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Candidal mediastinitis: an emerging clinical entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Case report. Successful treatment of two cases of post-surgical sternal osteomyelitis, due to Candida krusei and Candida albicans, respectively, with high doses of triazoles (fluconazole, itraconazole).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Candida tropicalis arthritis in a patient with acute myeloid leukemia successfully treated with fluconazole: case report and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Ocular fluconazole treatment of Candida parapsilosis endophthalmitis after failed intravitreal amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Use of fluconazole in the treatment of candidal endophthalmitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Candidal mitral endocarditis and long-term treatment with fluconazole in a patient with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Medical treatment of recurrent candidemia in a patient with probable Candida parapsilosis prosthetic valve endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Successful treatment of fungal prosthetic valve endocarditis: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Candida prosthetic valve endocarditis: prospective study of six cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Pacemaker endocarditis due to Candida albicans: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fungal prosthetic valve endocarditis in 16 patients. An 11-year experience in a tertiary care hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Candida peritonitis due to peptic ulcer perforation: incidence rate, risk factors, prognosis and susceptibility to fluconazole and amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fungal peritonitis in patients on peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Candida lusitaniae infections in the era of fluconazole availability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Nosocomial candiduria: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fluconazole prophylaxis against fungal colonization and infection in preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Prospective study of fluconazole therapy in systemic neonatal fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

The treatment of systemic candidiasis in neonates with oral fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Candidal sepsis and meningitis in a very-low-birth-weight infant successfully treated with fluconazole and flucytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Candida lusitaniae osteomyelitis in a premature infant

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Fluconazole in the treatment of candidiasis in immunocompromised children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

Candida albicansEndophthalmitis in Brown Heroin Addicts: Response to Early Vitrectomy Preceded and Followed by Antifungal Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI473

21 January 2018

Identifiers

DOI

10.1093/JAC/DKI473

1 reference

2 August 2017

1 reference